BA
52
2
DVN
16
3
IP
70
2
QRVO
6
2
EIX
77
2
T
50
3
ROK
55
8
BIIB
26
2
WAT
47
5
TRV
53
-3
HCP
58
4
OXY
40
3
ZTS
47
2
DHR
35
3
ORLY
53
-3
TGNA
53
2
PRU
57
-3
IPG
49
10
HSY
34
3
UA
45
-3
BA
52
2
DVN
16
3
IP
70
2
QRVO
6
2
EIX
77
2
T
50
3
ROK
55
8
BIIB
26
2
WAT
47
5
TRV
53
-3
HCP
58
4
OXY
40
3
ZTS
47
2
DHR
35
3
ORLY
53
-3
TGNA
53
2
PRU
57
-3
IPG
49
10
HSY
34
3
UA
45
-3
Financhill
Back

Sarepta Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
31

SRPT
Sarepta Therapeutics

Last Price:
110.72
Seasonality Move:
16.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Sarepta Therapeutics Price Quote

$110.72
-0.14 (-0.13%)
(Updated: November 21, 2024 at 2:00 PM ET)

Sarepta Therapeutics Key Stats

Sell
31
Sarepta Therapeutics (SRPT) is a Sell
Day range:
$108.72 - $111.38
52-week range:
$78.67 - $173.25
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.42
P/B ratio:
8.19%
Volume:
1.1M
Avg. volume:
981.5K
1-year change:
33.47%
Market cap:
$10B
Revenue:
$1.2B
EPS:
$1.54

How Much Does Sarepta Therapeutics Make?

Is Sarepta Therapeutics Growing As A Company?

  • What Is Sarepta Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.41%
  • What Is Sarepta Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sarepta Therapeutics Stock Price Performance

What Is Sarepta Therapeutics 52-Week High & Low?

Sarepta Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sarepta Therapeutics?

Is Sarepta Therapeutics Cash Flow Positive?

  • What Is SRPT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$352.5M
  • What Is Sarepta Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $77.8M
  • What Is Sarepta Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$72.9M

Sarepta Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SRPT return on invested capital is 5.51%
  • What Is Sarepta Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 3.67%
  • What Is SRPT Return On Equity?
    ROE is a measure of profitability and is 12.48%

Sarepta Therapeutics Earnings Date & Stock Price

Sarepta Therapeutics Competitors

Sarepta Therapeutics Dividend Yield

Sarepta Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 66.97%
Revenue: 40.79% 15.33%

Analyst Recommendations

Buy Recommendations: 12
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 189.86
Upside from Last Price: 71.26%

Major Shareholders

  • How many SRPT shares are owned by institutional investors?
    149M SRPT shares are owned by institutional investors
  • How many SRPT shares are owned by insiders?
    15.5M SRPT shares are owned by insiders